Versor Investments LP Acquires Shares of 18,600 BioLife Solutions, Inc. $BLFS

Key Points

• Versor Investments LP acquired 18,600 shares of BioLife Solutions, Inc. valued at approximately $425,000, marking a significant investment in the medical equipment provider.
• Analysts have mixed ratings on BioLife Solutions, with Stephens setting a price target of $30.00 and Zacks upgrading to a "strong-buy" rating, while one firm downgraded their rating to "sell."
• BioLife Solutions reported a quarterly earnings miss, with a loss of ($0.33) EPS compared to the consensus estimate of ($0.02), although revenues outperformed expectations at $25.42 million.

Versor Investments LP bought a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 18,600 shares of the medical equipment provider's stock, valued at approximately $425,000.

Several other institutional investors have also recently added to or reduced their stakes in BLFS. Sei Investments Co. boosted its position in shares of BioLife Solutions by 0.5% in the first quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider's stock worth $2,695,000 after acquiring an additional 547 shares during the last quarter. Rhumbline Advisers boosted its position in shares of BioLife Solutions by 0.7% in the first quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider's stock worth $1,901,000 after acquiring an additional 566 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of BioLife Solutions by 18.6% in the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after acquiring an additional 663 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of BioLife Solutions by 5.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,508 shares of the medical equipment provider's stock worth $532,000 after acquiring an additional 1,047 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of BioLife Solutions in the fourth quarter worth approximately $31,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, major shareholder Casdin Partners Master Fund, L sold 500,000 shares of the company's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $24.40, for a total transaction of $12,200,000.00. Following the sale, the insider owned 6,707,165 shares in the company, valued at $163,654,826. This represents a 6.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold a total of 2,008,831 shares of company stock worth $47,499,658 in the last 90 days. Corporate insiders own 2.20% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on BLFS shares. HC Wainwright reissued a "buy" rating and issued a $32.00 target price (up from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. Wall Street Zen downgraded BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Stephens initiated coverage on BioLife Solutions in a research report on Tuesday, July 22nd. They set an "overweight" rating and a $30.00 price target for the company. Finally, Zacks Research raised BioLife Solutions to a "strong-buy" rating in a research report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. Based on data from MarketBeat, BioLife Solutions has an average rating of "Buy" and a consensus price target of $31.29.

BioLife Solutions Stock Up 3.3%

Shares of NASDAQ BLFS traded up $0.83 on Friday, hitting $25.91. The company had a trading volume of 652,188 shares, compared to its average volume of 557,506. BioLife Solutions, Inc. has a 12-month low of $19.10 and a 12-month high of $29.55. The business has a 50 day moving average of $22.32 and a two-hundred day moving average of $23.39. The firm has a market capitalization of $1.24 billion, a P/E ratio of -215.90 and a beta of 1.76.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The business had revenue of $25.42 million during the quarter, compared to analysts' expectations of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.